Phytosphingosine Hydrochloride

Verify with FDA CVM →

122 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
122
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Phytosphingosine Hydrochloride

Administration Routes

TopicalAuricular (Otic)OphthalmicUnknown

Species Affected

Dog 95
Cat 19
Human 8

Most Affected Breeds

Crossbred Canine/dog 11
Domestic Shorthair 9
Mixed (Dog) 9
Unknown 8
Dog (unknown) 7
Shih Tzu 6
Retriever - Labrador 5
Shepherd Dog - German 4
Terrier - Yorkshire 4
Beagle 3

Most Reported Reactions

Application site erythema 18
Pruritus 11
Erythema (for urticaria see Immune SOC) 9
Application site pruritus 8
Emesis 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Ear discharge 5
Hives (see also 'Skin') 5
Vomiting 5
Ataxia 5
Application site dermatitis 5
Anorexia 4

Outcome Breakdown

Recovered/Normal
52 (42.6%)
Ongoing
44 (36.1%)
Outcome Unknown
18 (14.8%)
Recovered with Sequela
8 (6.6%)

Data Summary

Metric Value
Total adverse event reports 122
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Phytosphingosine Hydrochloride Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 122 adverse event reports referencing Phytosphingosine Hydrochloride, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Phytosphingosine Hydrochloride. Reported administration routes include Topical, Auricular (Otic), Ophthalmic, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Phytosphingosine Hydrochloride reports are Dog (95 reports), Cat (19 reports), Human (8 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (11), Domestic Shorthair (9), Mixed (Dog) (9) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Phytosphingosine Hydrochloride are Application site erythema (18), Pruritus (11), Erythema (for urticaria see Immune SOC) (9), Application site pruritus (8). Of the 122 reports with a coded outcome, Recovered/Normal is the leading category at 42.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Phytosphingosine Hydrochloride.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial